10

ADMA Biologics, Inc. (NASDAQ: ADMA) went down by -5.17% from its latest closing price when compared to the 1-year high value of $6.96, while ADMA stocks collected -18.38% of loss with the last five trading sessions.

ADMA Biologics, Inc. (NASDAQ: ADMA) Worth an Investment?

ADMA Biologics, Inc. (NASDAQ: ADMA) The 36 Months beta value for ADMA stocks is at 2.94, while 6 of the analysts out of 8 who provided ratings for ADMA Biologics, Inc. stocks as a “buy” while 2 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $11.81 which is $8.28 above current price. ADMA currently has a short float of 12.36% and public float of 29.53M with average trading volume of 1.14M shares.

ADMA Market Performance

ADMA stocks went down by -18.38% for the week, with the monthly drop of -12.99% and a quarterly performance of 10.47%, while its annual performance rate touched -20.08%. The simple moving average for the period of the last 20 days is -10.39% for ADMA stocks with the simple moving average of -11.46% for the last 200 days.

Analysts’ Opinion on ADMA Biologics, Inc. (NASDAQ: ADMA)

Many brokerage firms have already submitted their reports for ADMA stocks, with H.C. Wainwright repeating the rating for ADMA shares by setting it to “Buy”. The predicted price for ADMA socks in the upcoming period according to H.C. Wainwright is $13 based on the research report published on April 15, 2019.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see ADMA stock at the price of $10. The rating they have provided for ADMA stocks is “Buy” according to the report published on February 7, 2019.

ADMA Stocks -4.89% Far from 50 Day Moving Average

After a stumble in the market that brought ADMA to its low price for the period of the last 52 weeks, ADMA Biologics, Inc. was unable to take a rebound, for now settling with -39.37% of loss for the given period.

The stock volatility was left at 6.87%, however, within the period of a single month, the volatility rate increased by 9.38%, while the shares sank at the distance of -9.83% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +1.20% upper at the present time.

In the course of the last 5 trading sessions, ADMA went down by -18.38%, which changed the moving average for the period of 200 days to the total of -32.80% of losses for the stock in comparison to the 20-day moving average settled at $4.69. In addition, ADMA Biologics, Inc. saw 76.57% in overturn over the period of a single year with a tendency to cut further gains.

ADMA Stock Insider Trading

Reports are indicating that there were more than several insider trading activities at ADMA Biologics, Inc. (ADMA), starting from Grossman Adam S, who bought 52,301 shares at the price of $4.78 back on Jun 08. After this action, Rushing now owns 796,301 shares of ADMA Biologics, Inc., valued at $249,999 with the latest closing price.

Grossman Adam S, the President and CEO of ADMA Biologics, Inc., bought 20,921 shares at the value of $4.78 during a trade that took place back on Jun 08, which means that Grossman Adam S is holding 32,527 shares at the value of $100,002 based on the most recent closing price.

ADMA Stock Fundamentals

The current profitability levels are settled at -331.99 for the present operating margin and -153.39 for gross margin. The net margin for ADMA Biologics, Inc. stands at -387.06. Total capital return value is set at -76.56, while invested capital returns managed to touch -89.28. Equity return holds the value -205.40%, with -62.40% for asset returns.

Based on ADMA Biologics, Inc. (ADMA), the company’s capital structure generated 223.69 points for debt to equity in total, while total debt to capital is set at the value of 69.11. Total debt to assets is settled at the value of 49.76 with long-term debt to equity ratio rests at 223.54 and long-term debt to capital is 69.06.

The value for Enterprise to Sales is 15.24 with debt to enterprise value settled at 0.34. The receivables turnover for ADMA Biologics, Inc. is 6.44 with the total asset turnover at the value of 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.63.